CELEX: 62015CA0124
Language: en
Date: 2016-02-17 00:00:00
Title: Case C-124/15: Judgment of the Court (First Chamber) of 17 February 2016 (request for a preliminary ruling from the Finanzgericht Hamburg — Germany) — Salutas Pharma GmbH v Hauptzollamt Hanover (Reference for a preliminary ruling — Common Customs Tariff — Tariff classification — Combined Nomenclature — Heading 3004 — Effervescent tablets containing 500 mg of calcium — Level of substance per recommended daily dose significantly higher than the recommended daily allowance to maintain general health or well-being)

25.4.2016   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 145/12
            
         Judgment of the Court (First Chamber) of 17 February 2016 (request for a preliminary ruling from the Finanzgericht Hamburg — Germany) — Salutas Pharma GmbH v Hauptzollamt Hanover
   (Case C-124/15) (1)
   
   ((Reference for a preliminary ruling - Common Customs Tariff - Tariff classification - Combined Nomenclature - Heading 3004 - Effervescent tablets containing 500 mg of calcium - Level of substance per recommended daily dose significantly higher than the recommended daily allowance to maintain general health or well-being))
   (2016/C 145/13)
   Language of the case: German
   
      Referring court
   
   Finanzgericht Hamburg
   
      Parties to the main proceedings
   
   
      Applicant: Salutas Pharma GmbH
   
      Defendant: Hauptzollamt Hanover
   
      Operative part of the judgment
   
   The Combined Nomenclature in Annex I to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and the statistical nomenclature and on the Common Customs Tariff, as amended by Commission Regulation (EC) No 1006/2011 of 27 September 2011 must be interpreted as meaning that a product, such as effervescent tablets with a calcium content of 500 mg per tablet that is used for the prevention and treatment of a calcium deficiency and to support a special therapy for the prevention and treatment of osteoporosis, and for which the maximum recommended daily dose for adults indicated on the label is 1 500 mg, falls within heading 3004 of that nomenclature.
   
      (1)  OJ C 178, 1.6.2015.